CasInvent Pharma
Area
Product
Treatment of oncological diseases
Client
B2B
Molecules effective against hematopoietic and solid tumors.
CasInvent is developing small molecules that represent the first highly selective casein kinase 1 (CK1) α/δ/ε inhibitors of their kind. They are anti-cancer agents with a novel mechanism of action, effective against hematopoietic and solid tumors. CasInvent has developed and validated advanced candidate molecules with optimal in vivo profiles suitable for further clinical development.
Unique selling points:
- The first highly selective inhibitors of casein kinase 1.
- New mechanism of action.
- Robust patent protection.
Incubation
Challenge 1/2024
Technology readiness
- Development
- Proof of concept
- Prototype
- First implementation
- Extensive implementation
Similar startups
Vetee.ai
Ecosystem for pets.
ScienceTrack ZETA
An intuitive tool for managing laboratory animal data.
BrainBeams
Wearable neurostimulator to support concentration.
MarbleMat
Lipid particles to increase the absorption of substances.
MAIA LABS
An AI tool to improve lesion diagnosis in endoscopic…
VDI UHF-ECG for clinical medicine
Ultra-high-frequency ECG for the diagnosis of disorders of…
AndroidAPS
An app to make life easier for diabetics.
Sophomer
Materials replacing materials of animal origin in…
Preagon Biotech
Globally unique selective and environmentally friendly…
PiccoWASP Surgical Microdrill
PiccoWASP Surgical Microdrill.
Nanteo Solution
A portable device that performs immunochemical tests using…
Lightly
Portable device for the analysis of counterfeit medicines.